Probable Cerebral Amyloid Angiopathy–Related Inflammation Associated With Sitravatinib: A Case Report. Issue 2 (April 2022)

• Record Type: Journal Article
• Authors: Ray, Christopher; Dionne, Kalen
• Is Part Of: Neurology. Volume 12:Issue 2(2022)
• Page Start: e4
• Page End: e6
• Publication Date: 2022-04
• Subjects: Nervous system -- Diseases -- Periodicals; Neurology -- Periodicals; Neurology -- United States -- Periodicals; 616.8
• DOI: 10.1212/CPJ.0000000000001162
• Languages: English
• ISSNs: 2163-0402

Abstract

Abstract : Background and Objectives: We present the case of a 67-year-old man who developed encephalopathy, headaches, and seizure activity after initiating treatment with the novel tyrosine kinase inhibitor, sitravatinib. Methods: The patient was identified in routine clinical practice. Results: Brain MRI revealed lobar microhemorrhages and bihemispheric vasogenic edema. The patient met the criteria for probable cerebral amyloid angiopathy–related inflammation (CAA-ri) and responded favorably to high-dose methylprednisolone. Discussion: This report of neurologic autoimmunity in a patient receiving sitravatinib opens new lines of inquiry into the pathophysiology of CAA-ri. We emphasize the importance of early recognition and treatment of CAA-ri among patients receiving immunomodulatory chemotherapy.